ERBB2 and breast carcinoma: This study aimed to evaluate the transcriptome of HER2+ breast cancer patients and, according to their response to chemotherapy (sensitivity or resistance), to identify differentially expressed genes (DEGs) that could be useful in predicting patient outcomes after neoadjuvant chemotherapy treatment.